Bionic implants

Grader A: partial

Eversense, a fully implanted glucose sensor reporting to a phone app, was FDA approved in June 2018 and sold by prescription, matching the biometric-implant reading. It is one niche product (a few-mm sensor, not microscopic), and implanted sensing with closed-loop feedback beyond cardiac devices remained limited by 2021.

Test: D37 Horizons: such implants available to ordinary patients outside trials by 2021 (earlier counts); a single niche product is partial.

• FDA Approves World's First Long-Term Implantable Continuous Glucose Monitoring System for Marketing in United States (2018-06-21): Eversense implantable CGM sensor (90 days) approved for marketing in the US.

Grader B: partial

Senseonics' Eversense, a fully implanted glucose sensor with phone alerts, was FDA-approved June 2018 and sold from July 2018; it later integrated with insulin pumps (2024). It is a single niche product and not microscopic; no general class of 'bionic' micro-implants exists. Real but limited.

Test: Implanted biometric-sensing products with feedback could be bought by ordinary patients by 2021; partial if limited/niche.

• FDA Approves World's First Long-Term Implantable Continuous Glucose Monitoring System (2018-06-21): Implanted biometric sensor approved and distributed from July 2018.
• Fully-implantable CGM receives FDA authorization for integration with insulin pumps (2024-04-30): Feedback (pump integration) arrived only in 2024.